Xifaxan (rifaximin) typically takes the full 14-day course before most people notice meaningful improvement, with the clearest symptom relief appearing in the weeks after treatment ends. Some people feel better during the treatment itself, but clinical trial data shows the most significant gains around one week after finishing the pills.
The Standard Treatment Course
For IBS with diarrhea, the FDA-approved regimen is 550 mg taken three times a day for 14 days. That two-week window is the full treatment period, not an indefinite prescription. Unlike many medications you take continuously, Xifaxan is designed as a short course that produces benefits lasting well beyond the last dose.
The drug works almost entirely inside your gut. Less than 0.4% of each dose gets absorbed into your bloodstream. About 97% passes through your digestive tract unchanged and exits in your stool. This is by design: Xifaxan reshapes the bacterial environment in your intestines rather than acting on your whole body, which is also why it tends to cause fewer side effects than traditional antibiotics.
When Symptom Relief Actually Begins
In the large TARGET clinical trials, a significantly greater percentage of patients hit a meaningful response threshold as early as one week after finishing the 14-day course. That means for many people, noticeable improvement in pain, bloating, and stool consistency starts around week three from when they first swallowed the pill, not during the first few days of treatment.
Trial data showed that patients who responded experienced adequate relief of global IBS symptoms and bloating for at least two of the first four weeks of treatment. The benefits then continued to hold for at least five weeks after the course ended. So the realistic timeline looks something like this: you take the medication for two weeks, start feeling noticeably better in the days or weeks following, and that improvement can persist for weeks to months.
Some people do report feeling a difference within the first week of treatment, particularly with bloating. But if you’re five or six days in and don’t feel dramatically different, that’s completely normal. The medication is still doing its work on gut bacteria, and the downstream effects on your symptoms take time to materialize.
What to Expect During Treatment
The most common side effects during the 14-day course are stomach pain, upset stomach, and occasional abdominal swelling. These tend to be mild for most people. Because the drug stays in the gut and barely enters the bloodstream, the systemic side effects you might associate with other antibiotics (yeast infections, widespread digestive disruption) are less common.
It’s worth knowing that some people feel temporarily worse before they feel better, particularly with bloating. This can happen as the bacterial balance in the gut shifts. If side effects are manageable, it’s generally worth completing the full course rather than stopping early.
If Symptoms Come Back
IBS-D symptoms do return for some people after the initial course wears off. The FDA allows retreatment with the same 14-day regimen if symptoms recur. Previously, guidelines capped retreatment at three courses, but updated criteria from 2024 removed that limit, meaning your doctor can prescribe additional rounds as needed based on your symptom pattern.
The key criterion for retreatment is that moderate to severe symptoms (pain, bloating, diarrhea) continue or return despite the previous course. You don’t need to wait a specific amount of time before retreating, but your doctor will want to confirm that you genuinely responded the first time and that symptoms have meaningfully returned rather than never improved.
Timeline for Hepatic Encephalopathy
If you’re taking Xifaxan for hepatic encephalopathy (a complication of liver disease that affects brain function), the timeline and dosing are different. In this case, Xifaxan is taken continuously as a preventive medication, not as a short course. Over a six-month trial period, patients on rifaximin had a 58% lower risk of experiencing a breakthrough episode compared to placebo. Only 22% of treated patients had a recurrence, versus 46% on placebo. Hospitalizations related to the condition dropped by 50%.
For hepatic encephalopathy, the benefit is cumulative and preventive. You won’t feel a dramatic change on day one because the goal is to prevent future episodes rather than treat an acute symptom.
SIBO and Re-Testing
Many people take Xifaxan off-label for small intestinal bacterial overgrowth (SIBO), even though the drug is formally approved for IBS-D. If your doctor prescribed it for SIBO and you plan to re-test with a breath test afterward, clinical guidelines recommend waiting at least four weeks after finishing the antibiotic course before testing. Testing too soon can produce inaccurate results because the bacterial populations need time to stabilize.
For SIBO, symptom improvement often follows a similar trajectory to IBS-D: gradual improvement during the course with the most noticeable changes in the weeks following. If your symptoms haven’t improved meaningfully by about three to four weeks after finishing, that’s useful information for your doctor in deciding next steps, whether that’s a repeat course, a different treatment approach, or additional testing.